Medical device company Merit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue in Q4 CY2025, with sales up 10.9% year on year to $393.9 million. The company’s full-year revenue guidance of $1.62 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $0.93 per share was 2.5% below analysts’ consensus estimates.
Traffic solutions company Verra Mobility (NYSE:VRRM) announced better-than-expected revenue in Q4 CY2025, with sales up 16.4% year on year to $257.9 million. The company expects the full year’s revenue to be around $1.03 billion, close to analysts’ estimates. Its non-GAAP profit of $0.30 per share was 4.1% below analysts’ consensus estimates.
Professional services firm Huron Consulting Group (NASDAQ:HURN) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 10.7% year on year to $442 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.82 billion at the midpoint. Its non-GAAP profit of $2.17 per share was 11.3% above analysts’ consensus estimates.
MMCAP International increased its stake in NexGen Energy during the fourth quarter, deepening exposure to the company’s Rook I uranium project in Canada. As governments extend reactor lifespans and reconsider nuclear expansion, attention is turning to future uranium supply and how quickly projects like Rook I can begin production.
Infrastructure equipment supplier SPX Technologies (NYSE:SPXC) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 19.4% year on year to $637.3 million. The company’s full-year revenue guidance of $2.57 billion at the midpoint came in 3.8% above analysts’ estimates. Its non-GAAP profit of $1.88 per share was 0.7% above analysts’ consensus estimates.
Real estate technology company eXp World (NASDAQ:EXPI) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 8.5% year on year to $1.19 billion. Its GAAP loss of $0.08 per share was significantly below analysts’ consensus estimates.
Given its solid fundamentals, strong balance sheet, steady cash flow generation, and promising growth outlook, Whitecap Resources appears well-positioned to appeal to income-focused investors seeking both stability and long-term return potential.
Medical products company UFP Technologies (NASDAQ:UFPT) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 3.4% year on year to $148.9 million. Its non-GAAP profit of $2.44 per share was 9.2% above analysts’ consensus estimates.
Aerospace and defense technology solutions provider Astronics Corporation (NASDAQ:ATRO) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 15.1% year on year to $240.1 million. On the other hand, next quarter’s revenue guidance of $225 million was less impressive, coming in 3.3% below analysts’ estimates. Its non-GAAP profit of $0.75 per share was 25% above analysts’ consensus estimates.
Self defense company AXON (NASDAQ:AXON) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 38.5% year on year to $796.7 million. The company’s full-year revenue guidance of $6 billion at the midpoint came in 74.4% above analysts’ estimates. Its non-GAAP profit of $2.15 per share was 34.5% above analysts’ consensus estimates.
Solar panel manufacturer First Solar (NASDAQ:FSLR) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 11.1% year on year to $1.68 billion. On the other hand, the company’s full-year revenue guidance of $5.05 billion at the midpoint came in 17.4% below analysts’ estimates. Its GAAP profit of $4.84 per share was 6.3% below analysts’ consensus estimates.
Personal computing and printing company HP (NYSE:HPQ) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.9% year on year to $14.44 billion. Its non-GAAP profit of $0.81 per share was 5.3% above analysts’ consensus estimates.
Mediterranean fast-casual restaurant chain CAVA (NYSE:CAVA) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 20.9% year on year to $275 million. Its GAAP profit of $0.04 per share was $0.01 above analysts’ consensus estimates.
Online fashion retailer Revolve (NASDAQ:RVLV) announced better-than-expected revenue in Q4 CY2025, with sales up 10.4% year on year to $324.4 million. Its GAAP profit of $0.26 per share was 57.8% above analysts’ consensus estimates.
Workday Inc. reported revenues of $2.53 billion, an increase of 14.5% from the same period last year, and marginally above Wall Street estimates of $2.52 billion, as per data from Fiscal.ai.
Payment technology company Marqeta (NASDAQ:MQ) announced better-than-expected revenue in Q4 CY2025, with sales up 26.7% year on year to $172.1 million. The company expects next quarter’s revenue to be around $164.1 million, close to analysts’ estimates. Its GAAP loss of $0 per share was $0.01 above analysts’ consensus estimates.
Enterprise software company Workday (NASDAQ:WDAY) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 14.5% year on year to $2.53 billion. Its non-GAAP profit of $2.47 per share was 6.4% above analysts’ consensus estimates.
Global payments company Flywire (NASDAQ:FLYW) announced better-than-expected revenue in Q4 CY2025, with sales up 39.7% year on year to $157.5 million. Its GAAP loss of $0 per share was $0.01 above analysts’ consensus estimates.
The company reported fourth quarter net income per diluted share of $4.84, which was well below analysts’ estimates of $5.24 per share, according to data from fiscal.ai.
Beer company Boston Beer (NYSE:SAM) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 4.1% year on year to $385.7 million. Its GAAP loss of $2.12 per share was 15.3% above analysts’ consensus estimates.
Marketing technology company Zeta Global (NYSE:ZETA) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 25.4% year on year to $394.6 million. Guidance for next quarter’s revenue was optimistic at $370 million at the midpoint, 2.1% above analysts’ estimates.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 21.5% year on year to $211.6 million. On the other hand, the company’s full-year revenue guidance of $855 million at the midpoint came in 0.7% below analysts’ estimates. Its GAAP loss of $0.07 per share was 66.7% above analysts’ consensus estimates.
